Patient-derived lab-grown brain organoids and their secreted particles are used to investigate personalized responses to Alzheimer’s therapies, offering a glimpse into precision treatment prediction.
Key Takeaways
- Patient-derived brain organoids replicate patient-specific Alzheimer’s biology and show variable drug responses in vitro
- Proteomic analysis of organoids and their extracellular vesicles revealed early Alzheimer’s-related protein biomarkers
- Patterns in organoid-derived extracellular particles may help predict which Alzheimer’s treatments will be effective